Published abstract at ESMO

Published abstract at ESMO

“Open label phase III study of arfolitixorin vs leucovorin in mFOLFOX-6 for first-line treatment of metastatic colorectal cancer: AGENT”

Our abstract highlighting the poster presentation at ESMO – European Society for Medical Oncology was published this week! The poster, detailing trial design of our global Phase 3 AGENT study in metastatic colorectal cancer, will be presented at 12 PM CEST on Sunday, September 29.

Read the complete abstract directly from the link on our website >>